Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· February 18, 2026

Sabre Q4 Earnings Call Highlights

View original at finance.yahoo.com
Sabre Q4 Earnings Call Highlights Sabre logo Key Points Management is pushing Sabre toward becoming AI-native, arguing agentic AI will increase demand for its transaction layer and launching agentic APIs and partnerships (PayPal/Mindtrip, BizTrip, Virgin Australia) including a ChatGPT plugin to embed conversational boo…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Sabre strongly disagrees with the view that AI tools could bypass Sabre's marketplace through direct supplier connections

    80% confidence
  • Sabre is in conversations with effectively all the meaningful large players in AI

    80% confidence
  • Fourth-quarter results were solid and broadly in line with expectations shared on the third-quarter call, though partially offset by impacts related to a U.S. government shutdown

    80% confidence
  • Q4 gross margin decline was primarily due to revenue mix and foreign exchange impacts from a weaker U.S. dollar

    80% confidence
  • 2025 was a challenging and dynamic year impacted by exogenous events, but the company met or exceeded fourth-quarter guidance and ended the year with positive momentum

    80% confidence
  • Cash interest in 2026 is expected to be about $470 million, up approximately $140 million year-over-year, primarily because Sabre no longer benefits from a prior paid-in-kind instrument

    80% confidence
  • Management currently expects mid-single-digit revenue growth in 2027, sustained adjusted EBITDA growth, and positive free cash flow in 2027

    80% confidence
  • The government shutdown's impacts were broader than expected due to lower inbound U.S. traffic and an increase in flight cancellations

    80% confidence
  • Sabre plans to keep pro forma adjusted technology expense and pro forma adjusted SG&A relatively flat over the next two to three years through an inflation offset program

    80% confidence
  • Conversational commerce will be a major channel shift, and agentic travel's potential is comparable to the emergence of online travel agencies decades earlier

    80% confidence
  • Sabre's role is underpinned by scale and proprietary capabilities, including over 50 petabytes of curated travel data, processing 14,000 transactions per second, and 11 billion shopping signals per month

    80% confidence
  • Sabre launched the first agentic APIs and MCP server for travel about six months ago, purpose-built for LLM consumption at enterprise scale

    80% confidence
  • IT solutions revenue is expected to grow mid-single digits in 2026, with quarterly revenue in the $140M to $150M range and growth weighted to the back half of the year

    80% confidence
  • 2026 free cash flow is expected to be negative $70 million, driven primarily by restructuring cash costs; excluding restructuring, free cash flow would be near breakeven

    80% confidence
  • AI systems need the foundational transaction layer Sabre provides to shop, price, book, and service travel, and the shift toward agentic AI could make Sabre more essential, not less

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com